GP-X Regimen In Advanced Triple Negative Breast Cancer Analysis

Objective:The review analysis61example advanced three negative breast cancerpatients accept the GP-X plan and the standard treatment TX-X plan treatment clinicalcurative effect and the untoward effect separately.Methods: Altogether collects March,2006to December,2012in the first Hospitalof Dalian medical university treatment later period three negative breast cancer patient61examples,34cases of patients receiving chemotherapy regimens of GP-X,27casesof patients receiving TX-X. GP-X:GEM:1000mg/（m2·d）d1、8, DDP:75mg/（m2·d）d2-3，q21d,6cycles totally；TX-X：TXT:75mg/m2d1；CAP:950mg/（m2·d）, po, bid，d1-14，q21d，6cycles totally； Two groups of patients were follow-up for X (CAP)capecitabine, maintenance treatment: CAP950（m2·d）, po, bid，d1-14，q21d，Treatmentuntil disease progression or intolerance. Evaluated after each group of patients aretwo-cycle, weekly safety assessment. GP-X group completed135cycles, patients atleast accept every two cycle GP chemotherapy, the average period of four cycles ofchemotherapy. TX-X patients completed a total of112cycles, tests for patients with atleast two cycles of chemotherapy,the median number of cycles of chemotherapy is four.Observed tow groups of patients with clinical efficacy and toxicity. Term evaluationaccording to RECIST solid tumor evaluation criteria, the physical examinationcombined with auxiliary examination way. Adverse reaction according to WHO toxicityis divided into0-IV level standard. Results:61patients of efficacy can be evaluated, the incidence in patients withlimited was82%, realistic probability of remission was39.3%. GP–X group and TX-Xgroup achieved complete remission（CR）were8.8%（3cases）and7.4%（2cases）,partialremission（PR）were29.4%（10cases）and33.3%（9cases）,stable（SD）were44.1%（15cases）and40.7%（11cases）,progression （PD）were17.6%（6cases）and18.5%（5cases）,no significant difference（P＞0.05%）. GP–X group and TX-X group diseasecontrol rates82.4%and81.5%,objective remission rate was38.2%and40.7%, disparitywas not provided with statistical sense（P＞0.05. GP–X group of patients with medianprogression free survival time(mPFS) of6.1months (1-15.5months) and the TX-Xgroup of patients with mPFS of5.8months(2-14months),disparity was not providedwith statistical sense（P＞0.05）.GP-X group of patients with treatment of single transfer position and more parts ofthe efficient transfer patients were58.3%and27.3%, disparity was provided withstatistical sense (P<0.05). TX-X group of patients with treatment of single transferposition and more parts of the efficient transfer patients were66.7%and27.8%,disparity was provided with statistical sense (P<0.05). GP-X group of patients withtreatment of the ECOG0-1points and2points of patients were38.1%and38.5%,disparity was not provided with statistical sense (P>0.05); the menopausal patients andthe non-menopausal patients were39.1%and36.4%, disparity was not provided withstatistical sense (P>0.05). TX-X group of patients with treatment of the ECOG0-1points and2points of patients were41.2%and40.0%, disparity was not provided withstatistical sense (P>0.05); the menopausal patients and the non-menopausal patientswere42.8%and33.3%, disparity was not provided with statistical sense (P>0.05).Test results presented: Most of the side effects observed object digestion reactionand inhibited medulla ossium,multi-grade I-II reaction, III-IV reaction less, and arereversible. The probability of occurrence of hand-foot syndrome, the experimentalgroup was more than the control group,14.7%and51.9%, respectively, disparity wasnot provided with statistical sense (P <0.05); The experimental group than controlgroup in platelet decline in the incidence of high,55.9%and18.5%, respectively,disparity was provided with statistical sense (P <0.05); Control group norash occurs, the experimental group the incidence of rash was20.6%, disparity wasprovided with statistical sense (P <0.05). The experimental group and control group ofwhite blood cells decline, N and V，Liver and renal injury, hair loss is91.2%and81.5%respectively,55.9%and48.1%,8.8%and14.8%,5.9%and3.7%,32.4%and33.3%,disparity was not provided with statistical sense (P>0.05).Conclusion:1、 The GP-X group and TX-X group for advanced triple negativebreast cancer,ORR was38.2%and40.7%respectively, DCR was82.4%and81.5%respectively, mPFS were6.1months and5.8months, and have a better effect the twogroup can be advanced triple negative breast cancer chemotherapy, disparity was notprovided with statistical sense.2、The GP-X group of patients with treatment of single transfer position was betterthan more parts of the efficient transfer position, disparity was provided with statisticalsense, a better effect for the ECOG0-1points and2points of patients, the menopausalpatients and the non-menopausal patients, disparity was not provided with statisticalsense.3、 In the GP-X group and the TX-X group, the main adverse reactions weregastrointestinal reaction and medulla ossium transplantation, The probability ofoccurrence of hand-foot syndrome, the experimental group wai more than the controlgroup, the experimental group in soterocyte decrease, rash was significantly higher thanthe control group, disparity was provided with statistical sense, the remaining nosignificant statistical differences of adverse reaction, two groups of patients withadverse reaction were tolerable.4、According to control TX-X group, from the scheme of the treatment level andside effect, GP-X plan can be recommended for the advanced triple negative breastcancer.